- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03302845
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
April 23, 2018 updated by: Lexicon Pharmaceuticals
A Phase 1, Open-label, Parallel Group, Drug-drug Pharmacokinetic Interaction Study to Evaluate the Effects of Multiple-dose Omeprazole and Famotidine on the Absorption of Single-dose Telotristat Ethyl in Healthy Male and Female Subjects
This drug-drug interaction study will evaluate the impact of two different acid reducing agents (from two different drug classes) co-administered with a single dose of telotristat ethyl.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75247
- Covance Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Healthy adult males or females ≥18 to ≤ 65 years of age at the time of Screening:
- Females of non-childbearing potential are to be surgically sterile (documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy) or postmenopausal (defined as at least 12 months of spontaneous amenorrhea). Females of childbearing potential must agree to use an adequate method of contraception during the study from CRU admission through Safety Follow-up. Adequate methods of contraception for subjects or partner include condom, diaphragm, or cervical cap used in conjunction with spermicidal gel, foam, cream, film, or suppository. Hormonal contraception is NOT acceptable in this study. If necessary, follicle-stimulating hormone (FSH) results >40 IU/L at Screening are confirmatory in the absence of a clear postmenopausal history.
- Nonsterile male subjects with sexual partners of childbearing potential must agree to use adequate methods of contraception from CRU admission through Safety Follow-up. Adequate methods of contraception for subjects or partner include the following: condom with spermicidal gel, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections, progesterone implant (ie, Implanon®), NuvaRing®, Ortho Evra®; if a subject is not sexually active, but becomes active, he or his partner should use medically accepted forms of contraception.
- Body mass index ≥18.0 to ≤32.0 kg/m2 at Screening and Baseline/predose Day 1
- Willing to adhere to the prohibitions and restrictions specified in this protocol
- Able to comprehend and willing to sign an informed consent form (ICF)
- All laboratory values at Screening and CRU admission fall within normal range or are evaluated as not clinically significant (NCS) by the Investigator if outside normal range.
- Has no clinically meaningful abnormal findings during Screening and CRU admission physical examination, Screening and Baseline ECG, or Screening and Baseline vital signs
- Has the ability to understand and communicate the requirements of the study and is willing to comply with all study procedures
- Has not consumed and agrees to abstain from taking any dietary supplements, herbal products (eg, St. John's wort, garlic, or milk thistle), over-the-counter medications (OTC), supratherapeutic doses of vitamins, or prescription drugs (except as authorized by the Investigator AND Medical Monitor) from 14 days prior to CRU admission through the Safety Follow-up Visit
- Has not consumed alcohol-containing beverages for 3 days prior to CRU admission (as confirmed by alcohol breath analyzer) and agrees not to consume alcohol through the Safety Follow-up Visit
- Has not used tobacco- and/or nicotine-containing products within 60 days prior to the CRU admission and agrees to abstain from using tobacco- and/or nicotine-containing products, including e-cigarettes, through the Safety Follow-up Visit
Exclusion Criteria:
- History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, endocrinologic, hematological, or gastrointestinal (GI) abnormality
- Participation in another investigational study within 30 days of CRU admission
- Receipt of any protein- or antibody-based therapeutic agents (eg, growth hormones or monoclonal antibodies) within 3 months prior to Screening. Note: Influenza vaccine will be allowed if administered >21 days prior to CRU admission.
- Prior exposure to TE
- History of any serious adverse reaction or hypersensitivity to any inactive component of TE (ie, microcrystalline cellulose, croscarmellose sodium [disintegrant], talc, silicone dioxide, and magnesium stearate [non-bovine]), unless reaction is deemed irrelevant to the study by the Investigator and Sponsor
- History of malabsorption, bariatric surgery, gastric surgery, cholecystectomy, short-bowel syndrome, or GI surgery that may induce malabsorption
- History of any serious adverse reaction or hypersensitivity to any component of OMP or FTE
- History of any active infection within 14 days prior to first drug administration, if deemed clinically significant by the Investigator and/or Sponsor
- Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens
- Existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism, or excretion of TE (appendectomy and hernia repair are acceptable)
- Concurrent conditions that could interfere with safety and/or tolerability measurements
- Subject has donated plasma within 7 days of first drug administration.
- Subject has donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to first drug administration.
- Women who are breastfeeding or are planning to become pregnant during the study
- eGFR ≤ 89 ml/min/1.73 m2
- Positive pregnancy test (females only)
- Positive urine screen for selected drugs of abuse and cotinine at Screening or CRU admission
- Consumption of caffeine- and/or xanthine-containing products (cola, coffee, tea, chocolate, etc.) within 72 hours prior to CRU admission (Day 0) and throughout the study
- Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange-containing products within 72 hours prior to CRU admission (Day 0) and throughout the study
- Need for dietary restrictions, unless the restrictions are approved by the Investigator and Sponsor
- Inability or difficulty swallowing whole tablets
- Poor venous access as defined by the Investigator or a designee
- Any other condition that compromises the ability of the subject to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the Investigator or medical monitor
- Unable or unwilling to communicate or cooperate with the Investigator for any reason
- Employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Omeprazole
Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
|
Omeprazole 40 mg capsule
Telotristat ethyl 250 mg tablet
|
EXPERIMENTAL: Famotidine
Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
|
Telotristat ethyl 250 mg tablet
Famotidine 40 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed concentration of telotristat ethyl
Time Frame: 7 days
|
Maximum observed concentration of telotristat ethyl
|
7 days
|
Time of maximum observed concentration of telotristat ethyl
Time Frame: 7 days
|
Time of maximum observed concentration of telotristat ethyl
|
7 days
|
Area under the plasma concentration-time curve beginning from the first dose until the last quantifiable concentration of telotristat ethyl
Time Frame: 7 days
|
Area under the plasma concentration-time curve beginning from the first dose until the last quantifiable concentration of telotristat ethyl
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: Up to 13 days
|
Number of adverse events throughout the duration of the study
|
Up to 13 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 21, 2017
Primary Completion (ACTUAL)
October 23, 2017
Study Completion (ACTUAL)
November 7, 2017
Study Registration Dates
First Submitted
October 2, 2017
First Submitted That Met QC Criteria
October 2, 2017
First Posted (ACTUAL)
October 5, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 25, 2018
Last Update Submitted That Met QC Criteria
April 23, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LX1606.1-110-NRM
- LX1606.110 (OTHER: Lexicon Pharmaceuticals, Inc.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-drug Interaction
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
University of Southern CaliforniaRecruitingDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingDrug Drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationDrug-drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug Drug InteractionKorea, Republic of
-
ItalfarmacoCompletedDrug-Drug InteractionPortugal
-
Aurinia Pharmaceuticals Inc.CompletedDrug-drug InteractionUnited States
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Nanjing Yoko Biomedical Co., Ltd.CompletedDrug-drug InteractionChina
Clinical Trials on Omeprazole 40 MG
-
Damascus HospitalCompletedPeptic Ulcer Hemorrhage | Marginal Ulcer | Gastroduodenal UlcerSyrian Arab Republic
-
Dr. Reddy's Laboratories LimitedCompleted
-
Maria Sklodowska-Curie National Research Institute...Centre of Postgraduate Medical EducationCompletedBarretts Esophagus With Low Grade Dysplasia
-
Tobira Therapeutics, Inc.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daniel FreedbergCompleted
-
Genencell Co. Ltd.Recruiting
-
Xspray Pharma ABAxis Clinicals LimitedCompletedPharmacokinetics | Drug InteractionsUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Washington University School of MedicineCompletedDyspepsia | Helicobacter Pylori InfectionUnited States